|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM179B |
Gene summary for TMEM179B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM179B | Gene ID | 374395 |
| Gene name | transmembrane protein 179B | |
| Gene Alias | TMEM179B | |
| Cytomap | 11q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0000323 | UniProtAcc | Q7Z7N9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 374395 | TMEM179B | LZE2D | Human | Esophagus | HGIN | 3.80e-04 | 6.36e-01 | 0.0642 |
| 374395 | TMEM179B | LZE2T | Human | Esophagus | ESCC | 2.35e-04 | 1.36e+00 | 0.082 |
| 374395 | TMEM179B | LZE4T | Human | Esophagus | ESCC | 1.32e-18 | 7.88e-01 | 0.0811 |
| 374395 | TMEM179B | LZE5T | Human | Esophagus | ESCC | 7.76e-05 | 9.26e-01 | 0.0514 |
| 374395 | TMEM179B | LZE7T | Human | Esophagus | ESCC | 1.64e-10 | 5.47e-01 | 0.0667 |
| 374395 | TMEM179B | LZE8T | Human | Esophagus | ESCC | 1.87e-21 | 8.70e-01 | 0.067 |
| 374395 | TMEM179B | LZE20T | Human | Esophagus | ESCC | 4.27e-11 | 8.27e-01 | 0.0662 |
| 374395 | TMEM179B | LZE22D1 | Human | Esophagus | HGIN | 4.12e-02 | 2.97e-01 | 0.0595 |
| 374395 | TMEM179B | LZE22T | Human | Esophagus | ESCC | 1.46e-03 | 9.86e-01 | 0.068 |
| 374395 | TMEM179B | LZE24T | Human | Esophagus | ESCC | 1.39e-42 | 2.02e+00 | 0.0596 |
| 374395 | TMEM179B | LZE21T | Human | Esophagus | ESCC | 4.31e-02 | 3.70e-01 | 0.0655 |
| 374395 | TMEM179B | LZE6T | Human | Esophagus | ESCC | 7.20e-06 | 7.49e-01 | 0.0845 |
| 374395 | TMEM179B | P1T-E | Human | Esophagus | ESCC | 1.17e-08 | 1.03e+00 | 0.0875 |
| 374395 | TMEM179B | P2T-E | Human | Esophagus | ESCC | 2.01e-53 | 1.00e+00 | 0.1177 |
| 374395 | TMEM179B | P4T-E | Human | Esophagus | ESCC | 4.88e-73 | 2.30e+00 | 0.1323 |
| 374395 | TMEM179B | P5T-E | Human | Esophagus | ESCC | 8.17e-61 | 1.57e+00 | 0.1327 |
| 374395 | TMEM179B | P8T-E | Human | Esophagus | ESCC | 2.49e-88 | 2.17e+00 | 0.0889 |
| 374395 | TMEM179B | P9T-E | Human | Esophagus | ESCC | 2.63e-46 | 1.31e+00 | 0.1131 |
| 374395 | TMEM179B | P10T-E | Human | Esophagus | ESCC | 5.02e-46 | 9.96e-01 | 0.116 |
| 374395 | TMEM179B | P11T-E | Human | Esophagus | ESCC | 3.89e-30 | 1.44e+00 | 0.1426 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM179B | SNV | Missense_Mutation | novel | c.105N>G | p.Phe35Leu | p.F35L | Q7Z7N9 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| TMEM179B | SNV | Missense_Mutation | c.487N>T | p.His163Tyr | p.H163Y | Q7Z7N9 | protein_coding | tolerated(0.56) | benign(0.011) | TCGA-AA-3812-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TMEM179B | SNV | Missense_Mutation | rs770697657 | c.302G>A | p.Arg101His | p.R101H | Q7Z7N9 | protein_coding | tolerated(0.09) | possibly_damaging(0.599) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| TMEM179B | SNV | Missense_Mutation | rs770854047 | c.553N>A | p.Val185Met | p.V185M | Q7Z7N9 | protein_coding | tolerated(0.26) | benign(0.006) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM179B | SNV | Missense_Mutation | novel | c.544C>A | p.Leu182Ile | p.L182I | Q7Z7N9 | protein_coding | deleterious(0.01) | benign(0.192) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM179B | SNV | Missense_Mutation | novel | c.361N>A | p.Leu121Ile | p.L121I | Q7Z7N9 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| TMEM179B | SNV | Missense_Mutation | rs752707547 | c.331N>A | p.Val111Ile | p.V111I | Q7Z7N9 | protein_coding | tolerated(0.6) | benign(0) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM179B | SNV | Missense_Mutation | rs541728237 | c.644G>A | p.Arg215His | p.R215H | Q7Z7N9 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM179B | SNV | Missense_Mutation | rs769768771 | c.157N>A | p.Ala53Thr | p.A53T | Q7Z7N9 | protein_coding | tolerated(0.42) | benign(0.017) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| TMEM179B | SNV | Missense_Mutation | novel | c.625N>T | p.Asp209Tyr | p.D209Y | Q7Z7N9 | protein_coding | deleterious(0) | possibly_damaging(0.735) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |